Literature DB >> 8411068

Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 2. Correlations within individual patients.

L V Nicholson1, M A Johnson, K M Bushby, D Gardner-Medwin, A Curtis, I B Ginjaar, J T den Dunnen, J L Welch, T J Butler, E Bakker.   

Abstract

This report is the second part of a trilogy from a multidisciplinary study which was undertaken to record the relationships between clinical severity and dystrophin gene and protein expression. The aim in part 2 was to correlate the effect of gene deletions on protein expression in individual patients with well defined clinical phenotypes. Among the DMD patients, most of the deletions/duplications disrupted the open reading frame, but three patients had in frame deletions. Some of the intermediate D/BMD patients had mutations which were frameshifting while others were in frame. All of the deletions/duplications in the BMD patients maintained the open reading frame and 25/26 deletions in typical BMD group 5 started with exon 45. The deletion of single exon 44 was the most common mutation in patients from groups 1 to 3. Dystrophin was detected in sections and blots from 58% of the DMD patients with a size that was compatible with synthesis from mRNA in which the reading frame had been restored. Certain deletions were particularly associated with the occurrence of limited dystrophin synthesis in DMD patients. For example, 9/11 DMD patients missing single exons had some detectable dystrophin labelling compared with 10/24 who had deletions affecting more than one exon. All patients missing single exon 44 or 45 had some dystrophin. Deletions starting or finishing with exons 3 or 51 (8/9) cases were usually associated with dystrophin synthesis whereas those starting or finishing with exons 46 or 52 (11/11) were not. Formal IQ assessments (verbal, performance, and full scores) were available for 47 patients. Mean IQ score among the DMD patients was 83 and no clear relationship was found between gene mutations and IQ. The mutations in patients with a particularly severe deficit of verbal IQ were spread throughout the gene.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8411068      PMCID: PMC1016530          DOI: 10.1136/jmg.30.9.737

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  53 in total

1.  Additional dystrophin fragment in Becker muscular dystrophy patients: correlation with the pattern of DNA deletion.

Authors:  M Vainzof; M R Passos-Bueno; D Rapaport; R C Pavanello; M Zatz; D E Bulman
Journal:  Am J Med Genet       Date:  1992-10-01

2.  Additional dystrophin fragment in Becker muscular dystrophy may result from proteolytic cleavage at deletion junctions.

Authors:  A H Beggs; E P Hoffman; L M Kunkel
Journal:  Am J Med Genet       Date:  1992-10-01

3.  Mapping of dystrophin brain promoter: a deletion of this region is compatible with normal intellect.

Authors:  J T den Dunnen; L Casula; A Makover; B Bakker; D Yaffe; U Nudel; G J van Ommen
Journal:  Neuromuscul Disord       Date:  1991       Impact factor: 4.296

4.  Predicted and observed sizes of dystrophin in some patients with gene deletions that disrupt the open reading frame.

Authors:  L V Nicholson; K M Bushby; M A Johnson; J T den Dunnen; I B Ginjaar; G J van Ommen
Journal:  J Med Genet       Date:  1992-12       Impact factor: 6.318

5.  The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history.

Authors:  K M Bushby; D Gardner-Medwin
Journal:  J Neurol       Date:  1993-02       Impact factor: 4.849

6.  The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. II. Correlation of phenotype with genetic and protein abnormalities.

Authors:  K M Bushby; D Gardner-Medwin; L V Nicholson; M A Johnson; I D Haggerty; N J Cleghorn; J B Harris; S S Bhattacharya
Journal:  J Neurol       Date:  1993-02       Impact factor: 4.849

7.  A deletion including the brain promoter of the Duchenne muscular dystrophy gene is not associated with mental retardation.

Authors:  D Rapaport; M R Passos-Bueno; R I Takata; S Campiotto; S Eggers; M Vainzof; A Makover; U Nudel; D Yaffe; M Zatz
Journal:  Neuromuscul Disord       Date:  1992       Impact factor: 4.296

8.  Correlation of clinical and deletion data in Duchenne and Becker muscular dystrophy, with special reference to mental ability.

Authors:  S V Hodgson; S Abbs; S Clark; A Manzur; J Z Heckmatt; V Dubowitz; M Bobrow
Journal:  Neuromuscul Disord       Date:  1992       Impact factor: 4.296

9.  Dystrophin in frameshift deletion patients with Becker muscular dystrophy.

Authors:  S B Gangopadhyay; T G Sherratt; J Z Heckmatt; V Dubowitz; G Miller; M Shokeir; P N Ray; P N Strong; R G Worton
Journal:  Am J Hum Genet       Date:  1992-09       Impact factor: 11.025

10.  A 71-kilodalton protein is a major product of the Duchenne muscular dystrophy gene in brain and other nonmuscle tissues.

Authors:  D Lederfein; Z Levy; N Augier; D Mornet; G Morris; O Fuchs; D Yaffe; U Nudel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

View more
  11 in total

1.  Dystrophin hydrophobic regions in the pathogenesis of Duchenne and Becker muscular dystrophies.

Authors:  Yingyin Liang; Songlin Chen; Jianzong Zhu; Xiangxue Zhou; Chen Yang; Lu Yao; Cheng Zhang
Journal:  Bosn J Basic Med Sci       Date:  2015-05-20       Impact factor: 3.363

2.  Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials.

Authors:  Karen Anthony; Sebahattin Cirak; Silvia Torelli; Giorgio Tasca; Lucy Feng; Virginia Arechavala-Gomeza; Annarita Armaroli; Michela Guglieri; Chiara S Straathof; Jan J Verschuuren; Annemieke Aartsma-Rus; Paula Helderman-van den Enden; Katherine Bushby; Volker Straub; Caroline Sewry; Alessandra Ferlini; Enzo Ricci; Jennifer E Morgan; Francesco Muntoni
Journal:  Brain       Date:  2011-11-18       Impact factor: 13.501

3.  The correlation analysis of functional factors and age with duchenne muscular dystrophy.

Authors:  Il-Young Jung; Jong Hee Chae; Sue Kyung Park; Je Ho Kim; Jung Yoon Kim; Sang Joon Kim; Moon Suk Bang
Journal:  Ann Rehabil Med       Date:  2012-02-29

4.  Pseudometabolic presentation of dystrophinopathy due to a missense mutation.

Authors:  Aravindhan Veerapandiyan; Vandana Shashi; Yong-Hui Jiang; William Brian Gallentine; Kelly Schoch; Edward Clinton Smith
Journal:  Muscle Nerve       Date:  2010-12       Impact factor: 3.217

5.  Long-term persistence of donor nuclei in a Duchenne muscular dystrophy patient receiving bone marrow transplantation.

Authors:  Emanuela Gussoni; Richard R Bennett; Kristina R Muskiewicz; Todd Meyerrose; Jan A Nolta; Irene Gilgoff; James Stein; Yiu-Mo Chan; Hart G Lidov; Carsten G Bönnemann; Arpad Von Moers; Glenn E Morris; Johan T Den Dunnen; Jeffrey S Chamberlain; Louis M Kunkel; Kenneth Weinberg
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

6.  Detection of new paternal dystrophin gene mutations in isolated cases of dystrophinopathy in females.

Authors:  E Pegoraro; R N Schimke; K Arahata; Y Hayashi; H Stern; H Marks; M R Glasberg; J E Carroll; J W Taber; H B Wessel
Journal:  Am J Hum Genet       Date:  1994-06       Impact factor: 11.025

7.  Influence of dystrophin-gene mutation on mdx mouse behavior. I. Retention deficits at long delays in spontaneous alternation and bar-pressing tasks.

Authors:  C Vaillend; A Rendon; R Misslin; A Ungerer
Journal:  Behav Genet       Date:  1995-11       Impact factor: 2.805

Review 8.  Dilated cardiomyopathy and the dystrophin gene: an illustrated review.

Authors:  A Oldfors; B O Eriksson; M Kyllerman; T Martinsson; J Wahlström
Journal:  Br Heart J       Date:  1994-10

Review 9.  Duchenne and Becker Muscular Dystrophies: A Review of Animal Models, Clinical End Points, and Biomarker Quantification.

Authors:  Kristin Wilson; Crystal Faelan; Janet C Patterson-Kane; Daniel G Rudmann; Steven A Moore; Diane Frank; Jay Charleston; Jon Tinsley; G David Young; Anthony J Milici
Journal:  Toxicol Pathol       Date:  2017-10-03       Impact factor: 1.902

10.  Dystrophin gene mutation location and the risk of cognitive impairment in Duchenne muscular dystrophy.

Authors:  Peter J Taylor; Grant A Betts; Sarah Maroulis; Christian Gilissen; Robyn L Pedersen; David R Mowat; Heather M Johnston; Michael F Buckley
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.